Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bone Hormone Levels Predict Heart Failure Deaths

By LabMedica International staff writers
Posted on 22 Sep 2010
Circulating levels of a bone hormone are predictive of death and hospitalization for heart failure after acute coronary syndrome.

The level of osteoprotegerin (OPG), a member of the tumor necrosis factor receptor superfamily, can be measured using an enzyme-linked immunosorbent assay (ELISA) utilizing monoclonal antibodies.

A study OPG levels in the plasma of 1,229 patients with chronic heart failure (CHF) from 51 clinical centers, was carried out at Akershus University Hospital (Lørenskog, Norway). OPG levels were quantified by an in-house time-resolved immunofluorometric assay modified from an ELISA using commercially available monoclonal antibodies (R&D Systems; Abingdon, UK). The limit of detection for OPG was 15 ng/L.

During a median follow-up time of 3.9 years, 332 patients died and 791 patients died or were hospitalized because of cardiovascular causes. The median value of OPG was 1,509 ng/L (interquartile range: 1,102-2,185 ng/L). Circulating OPG levels were associated with a number of conventional risk markers. Patients with higher OPG levels were more likely to be older, to be female, to have more severe heart failure as evaluated by higher functional evaluation, and to have heart failure of ischemic etiology.

The main findings of this study of patients with CHF are that circulating concentrations of OPG are strongly and independently associated with all-cause mortality as well as with the incidence of the combined end point of mortality or cardio-vascular events. However, reclassification analyses suggest that the statistically significant association is unlikely to improve risk stratification of heart failure patients in a clinically meaningful way. The results showed that patients with the highest tertile of OPG were twice as likely to die during follow-up as the patients with the lowest tertile levels of OPG were.

Torbjørn Omland, M.D. Ph.D., the lead author of study, said, "The finding is interesting not only because it suggests that there is a link between bone metabolism and heart disease, but because it might help to identify heart failure patients who are at greatest risk. As medical practitioners, we can then target those patients earlier with intensified therapy.” The study was published in August 2010 issue of the American Heart Journal.

Related Links:
Akershus University Hospital
R&D Systems


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.